Growth Hormone Research Peptides

GHRH analogues bind the GHRH receptor on pituitary somatotrophs, increasing pulsatile GH release and downstream IGF-1. The DAC modification on CJC-1295 extends half-life through albumin binding.

How growth hormone peptides Ireland researchers choose GHRH analogues

GHRH analogues occupy a defined niche in pituitary research: rather than supplying exogenous growth hormone, they prompt the pituitary's own somatotroph cells to release it. This distinction matters for study design, since the resulting GH secretion remains pulsatile and subject to the negative feedback loops that natural GHRH exhibits, giving researchers a closer model of endogenous regulation.

Sermorelin, Tesamorelin and CJC-1295 all bind the same GHRH receptor but differ in stability and half-life, so a lab choosing among growth hormone peptides Ireland suppliers list will weigh which pharmacokinetic profile best fits a given protocol's sampling schedule and desired exposure window.

Compound relationships within the GHRH family

Sermorelin is a truncated 29-amino-acid fragment retaining full GHRH receptor activity but with a short half-life, making it useful for studying acute pulsatile release. Tesamorelin is a stabilised, full-length analogue most associated in the literature with visceral fat and IGF-1 axis research, giving a longer window of receptor engagement than Sermorelin.

CJC-1295 extends this family further: the base molecule shares Sermorelin's short action, while the DAC-modified version covalently associates with circulating albumin, extending detectable activity to several days. Researchers frequently pair CJC-1295 with Ipamorelin in blend formats to study combined GHRH/ghrelin receptor signalling.

Laboratory applications and model systems

GHRH analogues are used across in vitro pituitary cell cultures and in vivo rodent models examining pulsatile GH secretion, downstream IGF-1 production and metabolic endpoints such as lipolysis and lean mass. Tesamorelin in particular appears in visceral adiposity models referencing its distinct action on fat depots relative to other analogues.

Comparative protocols often run Sermorelin against CJC-1295 (with and without DAC) side by side to characterise differences in secretion profile shape — a single sharp GH pulse versus a sustained elevation — which has implications for interpreting downstream IGF-1 assay data.

Study design considerations for GHRH analogue research

Because GHRH analogues act on pulsatile systems, sampling frequency is a critical variable: infrequent timepoints can miss transient GH peaks following Sermorelin or standard CJC-1295 administration, while DAC-extended analogues demand longer observation windows to capture their flatter, prolonged profile.

Dose selection should also account for receptor desensitisation reported with repeated high-dose GHRH exposure in some models, and researchers should document reconstitution solvent and storage conditions alongside dosing records to keep results reproducible across replicate runs.

Handling, storage and quality assurance

Lyophilised GHRH analogues remain most stable refrigerated or frozen prior to reconstitution, and once reconstituted with bacteriostatic or sterile water should be kept refrigerated and used within the manufacturer's stated window to limit peptide degradation.

Every batch supplied for growth hormone peptides Ireland research should carry a certificate of analysis showing HPLC purity and LC-MS verified mass confirmation; Kensington Labs Ireland provides batch-specific COAs for Sermorelin, Tesamorelin and both CJC-1295 forms so research teams can confirm identity and purity before use.

Compound comparison

Research considerations

CJC-1295 with and without DAC give very different release profiles, so choose the form to match the study design.